Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Fresh from the biotech pipeline—2019

Nature Biotechnology volume 38, pages 126–131 (2020)Cite this article

The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and many months without permanent leadership at the FDA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Author information

Authors and Affiliations

  1. Yardley, PA, USA

    Chris Morrison

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Fresh from the biotech pipeline—2019. Nat Biotechnol 38, 126–131 (2020). https://doi.org/10.1038/s41587-019-0405-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0405-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing